Prospector
Profile
927-04
|
| |
| Northwest Biotherapeutics, Inc. |
NAICS |
541710 |
| 18701 120th Avenue NE, Suite 101
Bothell, Washington 98011 |
Description |
Biotechnology |
| (425) 608-3000 |
Employees |
3 |
| http://www.nwbio.com/ |
Revenue |
(mil) |
0.3900 |
| |
Income |
(mil) |
-8.5089 |
| |
Assets |
(mil) |
0.6310 |
| |
Liability |
(mil) |
12.0490 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Peterson Sullivan PLLC expressed substantial doubt on the ability of Northwest Biotherapeutics, Inc. to continue as a going concern due to its recurring losses from operations and accumulated deficit of $84.1million.
|
| |
|
Intellectual Property:
The Company seeks to protect commercially relevant proprietary technologies through patents both in the United States and abroad. The Company has 20 issued and licensed patents, including 9 in the United States and 11 in foreign jurisdictions. It also has 137 patent applications pending, including 15 in the United States and 122 in foreign jurisdictions. The patents cover the use of dendritic cells in DCVax® as well as targets for dendritic cell or monoclonal antibody therapy candidates. [SEC Filing 10-K 04-17-07]
|
| |
|
Description:
The biotechnology company is focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer.
|
| |
|
Officers:
Linda F. Powers (Chair); Alton L. Boynton (Pres., CEO & Dir.); Marnix L. Bosch (Chief Technical Officer); R. Steve Harris (Dir.)
|
| |
|
Auditor:
Peterson Sullivan PLLC
|
| |
|
Securities:
Common Stock-Symbol NWBO.OB; OTC BB;
42,346,088 common shares outstanding as of August 15, 2007.
|
| |
| |
| |
| return to main page |
